Clinical Trial Detail

NCT ID NCT02319369
Title Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-3032b in Hematological Malignancies
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Daiichi Sankyo Inc.
Indications

chronic lymphocytic leukemia

bone marrow cancer

acute lymphoblastic leukemia

acute myeloid leukemia

Therapies

Milademetan Tosylate

Age Groups: adult

No variant requirements are available.